Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa ME, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, He C, Ibrahim S, Beran M, Zavadil J, Nimer SD, Melnick A, Godley LA, Aifantis I, Levine RL.

Cancer Cell. 2011 Jul 12;20(1):11-24. doi: 10.1016/j.ccr.2011.06.001. Epub 2011 Jun 30.

2.

Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice.

Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R, Tsangaratou A, Rajewsky K, Koralov SB, Rao A.

Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14566-71. doi: 10.1073/pnas.1112317108. Epub 2011 Aug 22.

3.

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.

Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern MH, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard OA.

Cancer Cell. 2011 Jul 12;20(1):25-38. doi: 10.1016/j.ccr.2011.06.003. Epub 2011 Jun 30.

4.

Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.

Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE, Yang FC, Xu M.

Blood. 2011 Oct 27;118(17):4509-18. doi: 10.1182/blood-2010-12-325241. Epub 2011 Jul 29.

5.

The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.

Song SJ, Ito K, Ala U, Kats L, Webster K, Sun SM, Jongen-Lavrencic M, Manova-Todorova K, Teruya-Feldstein J, Avigan DE, Delwel R, Pandolfi PP.

Cell Stem Cell. 2013 Jul 3;13(1):87-101. doi: 10.1016/j.stem.2013.06.003.

6.

[Functional analysis of TET2 using a knockdown mouse model].

Shide K, Kameda T, Shimoda K.

Rinsho Ketsueki. 2015 Jun;56(6):657-65. doi: 10.11406/rinketsu.56.657. Japanese.

PMID:
26256876
7.

The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.

Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W.

Leukemia. 2014 Mar;28(3):485-96. doi: 10.1038/leu.2013.337. Epub 2013 Nov 13. Review.

PMID:
24220273
8.

TET2 is essential for survival and hematopoietic stem cell homeostasis.

Shide K, Kameda T, Shimoda H, Yamaji T, Abe H, Kamiunten A, Sekine M, Hidaka T, Katayose K, Kubuki Y, Yamamoto S, Miike T, Iwakiri H, Hasuike S, Nagata K, Marutsuka K, Iwama A, Matsuda T, Kitanaka A, Shimoda K.

Leukemia. 2012 Oct;26(10):2216-23. doi: 10.1038/leu.2012.94. Epub 2012 Apr 3.

PMID:
22469782
9.

Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.

Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR, Kuscu C, Hricik T, Ndiaye-Lobry D, Lafave LM, Koche R, Shih AH, Guryanova OA, Kim E, Li S, Pandey S, Shin JY, Telis L, Liu J, Bhatt PK, Monette S, Zhao X, Mason CE, Park CY, Bernstein BE, Aifantis I, Levine RL.

J Exp Med. 2013 Nov 18;210(12):2641-59. doi: 10.1084/jem.20131141. Epub 2013 Nov 11.

10.

Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells.

Kunimoto H, Fukuchi Y, Sakurai M, Sadahira K, Ikeda Y, Okamoto S, Nakajima H.

Sci Rep. 2012;2:273. doi: 10.1038/srep00273. Epub 2012 Feb 17.

11.

Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.

Rasmussen KD, Jia G, Johansen JV, Pedersen MT, Rapin N, Bagger FO, Porse BT, Bernard OA, Christensen J, Helin K.

Genes Dev. 2015 May 1;29(9):910-22. doi: 10.1101/gad.260174.115. Epub 2015 Apr 17.

12.

TET2 Mutation in Adult T-Cell Leukemia/Lymphoma.

Shimoda K, Shide K, Kameda T, Hidaka T, Kubuki Y, Kamiunten A, Sekine M, Akizuki K, Shimoda H, Yamaji T, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Kitanaka A.

J Clin Exp Hematop. 2015;55(3):145-9. doi: 10.3960/jslrt.55.145.

13.

[TET2 as a gatekeeper for hematologic malignancies].

Muto H, Sakata-Yanagimoto M, Chiba S.

Rinsho Ketsueki. 2015 Jun;56(6):651-6. doi: 10.11406/rinketsu.56.651. Japanese.

PMID:
26256875
14.

TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.

Nakajima H, Kunimoto H.

Cancer Sci. 2014 Sep;105(9):1093-9. doi: 10.1111/cas.12484. Epub 2014 Sep 3. Review.

15.

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.

Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, Quesnel B, Fenaux P, Bastie JN, Beyne-Rauzy O, Stamatoulas A, Dreyfus F, Ifrah N, de Botton S, Vainchenker W, Bernard OA, Birnbaum D, Fontenay M, Solary E; Groupe Francophone des Myélodysplasies.

Haematologica. 2009 Dec;94(12):1676-81. doi: 10.3324/haematol.2009.011205. Epub 2009 Oct 1.

16.

Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.

Campbell KJ, Bath ML, Turner ML, Vandenberg CJ, Bouillet P, Metcalf D, Scott CL, Cory S.

Blood. 2010 Oct 28;116(17):3197-207. doi: 10.1182/blood-2010-04-281071. Epub 2010 Jul 14.

17.

Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells.

Kunimoto H, McKenney AS, Meydan C, Shank K, Nazir A, Rapaport F, Durham B, Garrett-Bakelman FE, Pronier E, Shih AH, Melnick A, Chaudhuri J, Levine RL.

Blood. 2017 Mar 30;129(13):1779-1790. doi: 10.1182/blood-2016-06-721977. Epub 2017 Jan 11.

18.
19.

TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells.

Langlois T, da Costa Reis Monte-Mor B, Lenglet G, Droin N, Marty C, Le Couédic JP, Almire C, Auger N, Mercher T, Delhommeau F, Christensen J, Helin K, Debili N, Fuks F, Bernard OA, Solary E, Vainchenker W, Plo I.

Stem Cells. 2014 Aug;32(8):2084-97. doi: 10.1002/stem.1718.

20.

Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.

Chang YI, You X, Kong G, Ranheim EA, Wang J, Du J, Liu Y, Zhou Y, Ryu MJ, Zhang J.

Leukemia. 2015 Sep;29(9):1847-56. doi: 10.1038/leu.2015.85. Epub 2015 Mar 24.

Supplemental Content

Support Center